165 related articles for article (PubMed ID: 27161805)
1. Discovery of novel non-steroidal reverse indole mineralocorticoid receptor antagonists.
Ogawa AK; Bunte EV; Mal R; Lan P; Sun Z; Crespo A; Wiltsie J; Clemas J; Gibson J; Contino L; Lisnock J; Zhou G; Garcia-Calvo M; Jochnowitz N; Ma X; Pan Y; Brown P; Zamlynny B; Bateman T; Leung D; Xu L; Tong X; Liu K; Crook M; Sinclair P
Bioorg Med Chem Lett; 2016 Jun; 26(12):2866-2869. PubMed ID: 27161805
[TBL] [Abstract][Full Text] [Related]
2. Identification of spirooxindole and dibenzoxazepine motifs as potent mineralocorticoid receptor antagonists.
Lotesta SD; Marcus AP; Zheng Y; Leftheris K; Noto PB; Meng S; Kandpal G; Chen G; Zhou J; McKeever B; Bukhtiyarov Y; Zhao Y; Lala DS; Singh SB; McGeehan GM
Bioorg Med Chem; 2016 Mar; 24(6):1384-91. PubMed ID: 26897089
[TBL] [Abstract][Full Text] [Related]
3. Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series.
Cox JM; Chu HD; Yang C; Shen HC; Wu Z; Balsells J; Crespo A; Brown P; Zamlynny B; Wiltsie J; Clemas J; Gibson J; Contino L; Lisnock J; Zhou G; Garcia-Calvo M; Bateman T; Xu L; Tong X; Crook M; Sinclair P
Bioorg Med Chem Lett; 2014 Apr; 24(7):1681-4. PubMed ID: 24630411
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists.
Yang C; Shen HC; Wu Z; Chu HD; Cox JM; Balsells J; Crespo A; Brown P; Zamlynny B; Wiltsie J; Clemas J; Gibson J; Contino L; Lisnock J; Zhou G; Garcia-Calvo M; Bateman T; Xu L; Tong X; Crook M; Sinclair P
Bioorg Med Chem Lett; 2013 Aug; 23(15):4388-92. PubMed ID: 23777778
[TBL] [Abstract][Full Text] [Related]
5. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases.
Bärfacker L; Kuhl A; Hillisch A; Grosser R; Figueroa-Pérez S; Heckroth H; Nitsche A; Ergüden JK; Gielen-Haertwig H; Schlemmer KH; Mittendorf J; Paulsen H; Platzek J; Kolkhof P
ChemMedChem; 2012 Aug; 7(8):1385-403. PubMed ID: 22791416
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists.
Hasui T; Ohyabu N; Ohra T; Fuji K; Sugimoto T; Fujimoto J; Asano K; Oosawa M; Shiotani S; Nishigaki N; Kusumoto K; Matsui H; Mizukami A; Habuka N; Sogabe S; Endo S; Ono M; Siedem CS; Tang TP; Gauthier C; De Meese LA; Boyd SA; Fukumoto S
Bioorg Med Chem; 2014 Oct; 22(19):5428-45. PubMed ID: 25187277
[TBL] [Abstract][Full Text] [Related]
7. Mineralocorticoid Receptor Antagonists.
Nordqvist A; Granberg KL
Vitam Horm; 2019; 109():151-188. PubMed ID: 30678854
[TBL] [Abstract][Full Text] [Related]
8. Structure-Based Drug Design of Mineralocorticoid Receptor Antagonists to Explore Oxosteroid Receptor Selectivity.
Nordqvist A; O'Mahony G; Fridén-Saxin M; Fredenwall M; Hogner A; Granberg KL; Aagaard A; Bäckström S; Gunnarsson A; Kaminski T; Xue Y; Dellsén A; Hansson E; Hansson P; Ivarsson I; Karlsson U; Bamberg K; Hermansson M; Georgsson J; Lindmark B; Edman K
ChemMedChem; 2017 Jan; 12(1):50-65. PubMed ID: 27897427
[TBL] [Abstract][Full Text] [Related]
9. Predicting the relative binding affinity of mineralocorticoid receptor antagonists by density functional methods.
Roos K; Hogner A; Ogg D; Packer MJ; Hansson E; Granberg KL; Evertsson E; Nordqvist A
J Comput Aided Mol Des; 2015 Dec; 29(12):1109-22. PubMed ID: 26572910
[TBL] [Abstract][Full Text] [Related]
10. Modulating Mineralocorticoid Receptor with Non-steroidal Antagonists. New Opportunities for the Development of Potent and Selective Ligands without Off-Target Side Effects.
Martín-Martínez M; Pérez-Gordillo FL; Álvarez de la Rosa D; Rodríguez Y; Gerona-Navarro G; González-Muñiz R; Zhou MM
J Med Chem; 2017 Apr; 60(7):2629-2650. PubMed ID: 28051871
[TBL] [Abstract][Full Text] [Related]
11. Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion.
Bamberg K; Johansson U; Edman K; William-Olsson L; Myhre S; Gunnarsson A; Geschwindner S; Aagaard A; Björnson Granqvist A; Jaisser F; Huang Y; Granberg KL; Jansson-Löfmark R; Hartleib-Geschwindner J
PLoS One; 2018; 13(2):e0193380. PubMed ID: 29474466
[TBL] [Abstract][Full Text] [Related]
12. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development.
Kolkhof P; Bärfacker L
J Endocrinol; 2017 Jul; 234(1):T125-T140. PubMed ID: 28634268
[TBL] [Abstract][Full Text] [Related]
13. SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activity.
Nariai T; Fujita K; Mori M; Katayama S; Hori S; Matsui K
J Pharmacol Sci; 2011; 115(3):346-53. PubMed ID: 21358118
[TBL] [Abstract][Full Text] [Related]
14. Mineralocorticoid receptor modulators: a patent review (2007 - 2012).
Collin M; Niemann F; Jaisser F
Expert Opin Ther Pat; 2014 Feb; 24(2):177-83. PubMed ID: 24215301
[TBL] [Abstract][Full Text] [Related]
15. Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor.
Rogerson FM; Yao Y; Smith BJ; Fuller PJ
Clin Exp Pharmacol Physiol; 2004 Oct; 31(10):704-9. PubMed ID: 15554912
[TBL] [Abstract][Full Text] [Related]
16. Mineralocorticoid receptor antagonists attenuate pulmonary inflammation and bleomycin-evoked fibrosis in rodent models.
Lieber GB; Fernandez X; Mingo GG; Jia Y; Caniga M; Gil MA; Keshwani S; Woodhouse JD; Cicmil M; Moy LY; Kelly N; Jimenez J; Crawley Y; Anthes JC; Klappenbach J; Ma YL; McLeod RL
Eur J Pharmacol; 2013 Oct; 718(1-3):290-8. PubMed ID: 24012780
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of aryl sulfonamide-based nonsteroidal mineralocorticoid receptor antagonists.
Futatsugi K; Piotrowski DW; Casimiro-Garcia A; Robinson S; Sammons M; Loria PM; Banker ME; Petersen DN; Schmidt NJ
Bioorg Med Chem Lett; 2013 Dec; 23(23):6239-42. PubMed ID: 24157365
[TBL] [Abstract][Full Text] [Related]
18. Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy.
Piotrowski DW
J Med Chem; 2012 Sep; 55(18):7957-66. PubMed ID: 22866979
[No Abstract] [Full Text] [Related]
19. Biotransformation of the mineralocorticoid receptor antagonists spironolactone and canrenone by human CYP11B1 and CYP11B2: Characterization of the products and their influence on mineralocorticoid receptor transactivation.
Schiffer L; Müller AR; Hobler A; Brixius-Anderko S; Zapp J; Hannemann F; Bernhardt R
J Steroid Biochem Mol Biol; 2016 Oct; 163():68-76. PubMed ID: 27125452
[TBL] [Abstract][Full Text] [Related]
20. Mineralocorticoid receptor antagonists, a class beyond spironolactone--Focus on the special pharmacologic properties of eplerenone.
Seferovic PM; Pelliccia F; Zivkovic I; Ristic A; Lalic N; Seferovic J; Simeunovic D; Milinkovic I; Rosano G
Int J Cardiol; 2015 Dec; 200():3-7. PubMed ID: 26404746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]